Petros Pharmaceuticals, Inc. Accounts Receivable, Allowance for Credit Loss
Petros Pharmaceuticals, Inc. (PTPI) had Accounts Receivable, Allowance for Credit Loss of $134.23 thousand as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2025-03-31
- 2024-12-31: Accounts Receivable, Allowance for Credit Loss $134.23K.
- 2024-09-30: Accounts Receivable, Allowance for Credit Loss $207.60K.
- 2024-06-30: Accounts Receivable, Allowance for Credit Loss $177.33K.
- 2024-03-31: Accounts Receivable, Allowance for Credit Loss $153.04K.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2024-12-31 | $134.23K 10-K · filed 2025-03-31 |
| 2024-09-30 | $207.60K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $177.33K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $153.04K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $235.10K 10-K · filed 2025-03-31 |
| 2023-09-30 | $239.38K 10-Q · filed 2023-11-15 |
| 2023-06-30 | $211.37K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $243.08K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $206.87K 10-K · filed 2024-04-01 |
| 2022-09-30 | $274.03K 10-Q/A · filed 2022-11-15 |
| 2022-06-30 | $270.75K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $262.32K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $377.69K 10-Q · filed 2023-11-15 |
| 2021-09-30 | $303.75K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $246.54K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $231.78K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $228.80K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |